Table 3.
Clinical parameters of HAM/TSP patients at baseline and posttreatment of HuMikβ1.
| Group | Patient No. | Time course | EDSS | SNRS | T25‐FW | AI | IPEC |
|---|---|---|---|---|---|---|---|
| 1 | HAM #1 | Baseline | 6.5 | 75 | 11.2 | 3 | 16 |
| Week 12 | 6.5 | 55 | 27.5 | 6 | 18 | ||
| Week 18 | 6 | 64 | 16.8 | 4 | 18 | ||
| HAM #2 | Baseline | 6 | 72 | 10.2 | 4 | 13 | |
| Week 12 | 6 | 72 | 8.1 | 4 | 13 | ||
| Week 18 | 6 | 66 | 8.6 | 4 | 13 | ||
| HAM #3 | Baseline | 6.5 | 68 | 41.2 | 6 | 20 | |
| Week 12 | 6.5 | 64 | na | 6 | 21 | ||
| Week 18 | 7 | 65 | na | 7 | 22 | ||
| HAM #4 | Baseline | 7 | 73 | na | 7 | 24 | |
| Week 12 | 7.5 | 67 | na | 7 | 24 | ||
| Week 18 | 8 | 61 | na | 8 | 26 | ||
| 2 | HAM #5 | Baseline | 6.5 | 47 | 23.9 | 6 | 17 |
| Week 12 | 6.5 | 50 | 20.6 | 6 | 13 | ||
| Week 18 | 6.5 | 54 | 18.8 | 5 | 13 | ||
| HAM #6 | Baseline | 7 | 53 | na | 8 | 21 | |
| Week 12 | 7.5 | 51 | na | 8 | 20 | ||
| Week 18 | 7.5 | 51 | na | 8 | 19 | ||
| HAM #7 | Baseline | 8 | 55 | na | 8 | 24 | |
| Week 12 | 8 | 51 | na | 8 | 23 | ||
| Week 18 | 8 | 56 | na | 8 | 25 | ||
| 3 | HAM #8 | Baseline | 6.5 | 67 | 10.4 | 5 | 19 |
| Week 12 | 6.5 | 67 | 9.1 1 | 5 | 19 | ||
| Week 18 | 6.5 | 67 | 10.4 | 5 | 19 | ||
| HAM #9 | Baseline | 6 | 69 | 33.8 | 5 | 14 | |
| Week 12 | 6 | 69 | 39.7 | 5 | 14 | ||
| Week 18 | 6 | 69 | 33.8 | 5 | 14 |
EDSS, Expanded Disability Status Scale; SNRS, Scripps Neurologic Rating Scale; T25‐FW, Timed 25‐Foot Walk; AI, Ambulation Index; IPEC, Insituto de Pesquisa Clinica Evandro Chagas; na, not applicable.
1
At 9 weeks